{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:48:38Z","timestamp":1788281318795,"version":"build-2803163510"},"reference-count":158,"publisher":"Impact Journals, LLC","issue":"29","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,4,17]]},"DOI":"10.18632\/oncotarget.25024","type":"journal-article","created":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T06:26:56Z","timestamp":1523860016000},"page":"20855-20871","source":"Crossref","is-referenced-by-count":24,"title":["Hypertension in malignancy-an underappreciated problem"],"prefix":"10.18632","volume":"9","author":[{"given":"Jolanta","family":"Ma\u0142yszko","sequence":"first","affiliation":[{"name":"2nd Department of Nephrology and Hypertension with Dialysis Unit, Medical University in Bialystok, Bialystok, Poland"},{"name":"Department of Nephrology, Dialysis and Internal Medicine, Warsaw Medical University, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Ma\u0142yszko","sequence":"additional","affiliation":[{"name":"2nd Department of Nephrology and Hypertension with Dialysis Unit, Medical University in Bialystok, Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leszek","family":"Kozlowski","sequence":"additional","affiliation":[{"name":"Department of Oncological Surgery, Regional Cancer Center, Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaudia","family":"Kozlowska","sequence":"additional","affiliation":[{"name":"2nd Department of Nephrology and Hypertension with Dialysis Unit, Medical University in Bialystok, Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Ma\u0142yszko","sequence":"additional","affiliation":[{"name":"1st Department of Nephrology and Transplantology with Dialysis Unit, Medical University in Bialystok, Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2018,4,17]]},"reference":[{"key":"1","volume-title":"Cancer Treatment and Survivorship Facts & Figures 2015-2016","author":"American Cancer Society","year":"2016"},{"key":"2","unstructured":"World estimated cancer prevalence, adult population: both sexes. http:\/\/globocan.iarc.fr\/summary_table_site_prev.asp?selection=280&title=All+cancers+excl.+non-melanoma+skin+cancer&sex=0&africa=1&america=2&asia=3&europe=4&oceania=5&build=6&window=1&sort=15&submit=%A0Execute%A0 (Accessed on September 27, 2017)."},{"key":"3","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1200\/JCO.2012.45.2938","article-title":"Late cardiac effects of cancer treatment","volume":"30","author":"Cardinale","year":"2012","journal-title":"J Clin Oncol"},{"key":"4","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1038\/bjc.2014.37","article-title":"Cardiovascular sequelae in long-term survivors of young peoples\u2019 cancer: a linked cohort study","volume":"110","author":"Glaser","year":"2014","journal-title":"Br J Cancer"},{"key":"5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/annonc\/mdq609","article-title":"Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper","volume":"22","author":"Wedding","year":"2011","journal-title":"Ann Oncol"},{"key":"6","first-page":"263","article-title":"Hypertension in cancer patients","volume":"38","author":"Salahudeen","year":"2011","journal-title":"Tex Heart Inst J"},{"key":"7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/jnci\/djp440","article-title":"Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention","volume":"102","author":"Noonan","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"8","doi-asserted-by":"publisher","first-page":"5204","DOI":"10.1200\/JCO.2007.15.6331","article-title":"Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma","volume":"26","author":"Schmidinger","year":"2008","journal-title":"J Clin Oncol"},{"key":"9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/toxsci\/kfq378","article-title":"Cardiotoxicity associated with targeting kinase pathways in cancer","volume":"120","author":"Roberts","year":"2011","journal-title":"Toxicol Sci"},{"key":"10","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Harris","year":"2007","journal-title":"Lancet"},{"key":"11","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1634\/theoncologist.2009-0235","article-title":"Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies","volume":"15","author":"Brandes","year":"2010","journal-title":"Oncologist"},{"key":"12","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1093\/annonc\/mdp025","article-title":"Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis","volume":"20","author":"De Nunzio","year":"2009","journal-title":"Ann Oncol"},{"key":"13","doi-asserted-by":"publisher","first-page":"4649","DOI":"10.1200\/JCO.2010.29.9362","article-title":"Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study","volume":"28","author":"Fossa","year":"2010","journal-title":"J Clin Oncol"},{"key":"14","doi-asserted-by":"publisher","first-page":"4980","DOI":"10.1200\/JCO.2005.06.882","article-title":"Blood pressure and body mass index in long-term survivors of testicular cancer","volume":"23","author":"Bremnes","year":"2005","journal-title":"J Clin Oncol"},{"key":"15","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1093\/jnci\/djq216","article-title":"Testicular cancer survivorship: research strategies and recommendations","volume":"102","author":"Okunieff","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"16","first-page":"1358","article-title":"The long-term retention of platinum in human tissues following the administration of cisplatin or carboplatin for cancer chemotherapy","volume":"28A","author":"Smyth","year":"1992","journal-title":"Eur J Cancer"},{"key":"17","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(00)02044-4","article-title":"Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer","volume":"355","author":"Sleijfer","year":"2000","journal-title":"Lancet"},{"key":"18","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1161\/CIRCULATIONAHA.104.470849","article-title":"Antiangiogenesis mediates cisplatin-induced peripheral neuropathy: attenuation or reversal by local vascular endothelial growth factor gene therapy without augmenting tumor growth","volume":"111","author":"Weber","year":"2005","journal-title":"Circulation"},{"key":"19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1203\/00006450-199009000-00007","article-title":"Placental transfer of glucose and amino acids in intrauterine growth retardation: studies with substrate analogs in the awake guinea pig","volume":"28","author":"Persson","year":"1990","journal-title":"Pediatr Res"},{"key":"20","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ejphar.2010.09.085","article-title":"Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies","volume":"650","author":"Radwan","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"21","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1186\/1471-2407-14-915","article-title":"Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring","volume":"14","author":"Hajje","year":"2014","journal-title":"BMC Cancer"},{"key":"22","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline","volume":"35","author":"Jessup","year":"2017","journal-title":"J Clin Oncol"},{"key":"23","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Muggia","year":"1979","journal-title":"Ann Intern Med"},{"key":"24","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1200\/JCO.2004.06.033","article-title":"Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults","volume":"22","author":"Coiffier","year":"2004","journal-title":"J Clin Oncol"},{"key":"25","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s11906-007-0058-7","article-title":"Chemotherapy agents and hypertension: a focus on angiogenesis blockade","volume":"9","author":"Townsend","year":"2007","journal-title":"Curr Hypertens Rep"},{"key":"26","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1200\/JCO.2007.14.1242","article-title":"Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin\u2019s lymphoma","volume":"26","author":"Jacobson","year":"2008","journal-title":"J Clin Oncol"},{"key":"27","doi-asserted-by":"publisher","first-page":"3808","DOI":"10.1200\/JCO.2006.10.4976","article-title":"Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer","volume":"25","author":"Giordano","year":"2007","journal-title":"J Clin Oncol"},{"key":"28","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.jash.2014.08.009","article-title":"Pre-existing arterial hypertension as a risk factor for early left ventricular systolic dysfunction following (R)-CHOP chemotherapy in patients with lymphoma","volume":"8","author":"Torbicki","year":"2014","journal-title":"J Am Soc Hypertens"},{"key":"29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2459\/JCM.0b013e328365afb5","article-title":"ICARO (Italian CARdio-Oncological) Network. Role of hypertension on new onset congestive heart failure in patients receiving trastuzumab therapy for breast cancer","volume":"15","author":"Tarantini","year":"2014","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"30","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s11739-015-1362-x","article-title":"Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer","volume":"11","author":"Moja","year":"2016","journal-title":"Intern Emerg Med"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000065","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","author":"Ovbiagele","year":"2017","journal-title":"Hypertension"},{"key":"32","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/jch.12273","article-title":"Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis","volume":"16","author":"Shi","year":"2014","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"33","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Barisoni","year":"2008","journal-title":"N Engl J Med"},{"key":"34","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5414\/CNP71130","article-title":"Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution","volume":"71","author":"Flombaum","year":"2009","journal-title":"Clin Nephrol"},{"key":"35","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors","volume":"116","author":"Group","year":"2010","journal-title":"Cancer"},{"key":"36","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Schmidt-Wolf","year":"2007","journal-title":"N Engl J Med"},{"key":"37","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.2174\/138161212800626210","article-title":"Targeting mTOR pathways in human malignancies","volume":"18","author":"Sessa","year":"2012","journal-title":"Curr Pharm Des"},{"key":"38","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.2337\/db09-1324","article-title":"Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue","volume":"59","author":"Marette","year":"2010","journal-title":"Diabetes"},{"key":"39","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/ndt\/gfq617","article-title":"The podocyte as a direct target of immunosuppressive agents","volume":"26","author":"Schiffer","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"40","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1053\/j.ajkd.2010.10.048","article-title":"Hypertension after kidney transplant","volume":"57","author":"Vella","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"41","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.trre.2014.03.002","article-title":"Strategies for the management of adverse events associated with mTOR inhibitors","volume":"28","author":"Wellen","year":"2014","journal-title":"Transplant Rev (Orlando)"},{"key":"42","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ctrv.2010.11.001","article-title":"Cardiovascular effects of systemic cancer treatment","volume":"37","author":"Jassem","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"43","doi-asserted-by":"publisher","first-page":"7685","DOI":"10.1200\/JCO.2005.08.789","article-title":"Cardiotoxicity of cancer therapy","volume":"23","author":"Perry","year":"2005","journal-title":"J Clin Oncol"},{"key":"44","doi-asserted-by":"publisher","first-page":"246","DOI":"10.5935\/abc.20150011","article-title":"Hypertension in patients with cancer","volume":"104","author":"Martins Wde","year":"2015","journal-title":"Arq Bras Cardiol"},{"key":"45","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Suvorov","year":"2016","journal-title":"Lancet Oncol"},{"key":"46","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1159\/000227392","article-title":"Recombinant human erythropoietin in the treatment of cancer-related anaemia","volume":"51","author":"Vermaak","year":"1994","journal-title":"Oncology"},{"key":"47","first-page":"229","article-title":"The effect of subcutaneous r-HuEPO in cancer patients receiving chemotherapy with anemia: a preliminary report","volume":"60","author":"Chen","year":"1997","journal-title":"Zhonghua Yi Xue Za Zhi (Taipei)"},{"key":"48","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/CCO.0b013e32833aa9de","article-title":"Erythropoietin in cancer patients: pros and cons","volume":"22","author":"Plawny","year":"2010","journal-title":"Curr Opin Oncol"},{"key":"49","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1161\/01.CIR.0000061911.47710.8A","article-title":"The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis","volume":"107","author":"Rundle","year":"2003","journal-title":"Circulation"},{"key":"50","first-page":"H1054","article-title":"VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells","volume":"274","author":"Granger","year":"1998","journal-title":"Am J Physiol"},{"key":"51","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1113\/expphysiol.2004.028571","article-title":"Therapeutic angiogenesis and vasculogenesis for tissue regeneration","volume":"90","author":"Madeddu","year":"2005","journal-title":"Exp Physiol"},{"key":"52","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/j.1365-2796.2003.01297.x","article-title":"Manipulating angiogenesis in medicine","volume":"255","author":"Carmeliet","year":"2004","journal-title":"J Intern Med"},{"key":"53","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1161\/HYPERTENSIONAHA.110.160481","article-title":"Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors","volume":"56","author":"Humphreys","year":"2010","journal-title":"Hypertension"},{"key":"54","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1200\/JCO.2005.04.5740","article-title":"Angiogenesis inhibitors and hypertension: an emerging issue","volume":"24","author":"Sica","year":"2006","journal-title":"J Clin Oncol"},{"key":"55","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/annonc\/mdn713","article-title":"Management of hypertension in angiogenesis inhibitor-treated patients","volume":"20","author":"Spano","year":"2009","journal-title":"Ann Oncol"},{"key":"56","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.jacc.2012.01.069","article-title":"\u201cOn-target\u201d cardiac effects of anticancer drugs: lessons from new biology","volume":"60","author":"Eichmann","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"57","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Rogers","year":"2004","journal-title":"N Engl J Med"},{"key":"58","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1634\/theoncologist.2010-0002","article-title":"An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity","volume":"16","author":"Goldwasser","year":"2011","journal-title":"Oncologist"},{"key":"59","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1093\/annonc\/mds593","article-title":"Shorter bevacizumab infusions do not increase the incidence of proteinuria and hypertension","volume":"24","author":"Verma","year":"2013","journal-title":"Ann Oncol"},{"key":"60","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/JAHA.117.006278","article-title":"Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients","author":"Rassaf","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"61","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","article-title":"Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen","volume":"30","author":"Tellier","year":"2012","journal-title":"J Clin Oncol"},{"key":"62","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Castellano","year":"2011","journal-title":"Lancet"},{"key":"63","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1200\/JCO.2005.02.0503","article-title":"Mechanisms of hypertension associated with BAY 43-9006","volume":"24","author":"O\u2019Dwyer","year":"2006","journal-title":"J Clin Oncol"},{"key":"64","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/j.ejca.2011.03.033","article-title":"The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer","volume":"47","author":"Dimopoulos","year":"2011","journal-title":"Eur J Cancer"},{"key":"65","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"McCann","year":"2010","journal-title":"J Clin Oncol"},{"key":"66","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Ryan","year":"2012","journal-title":"J Clin Oncol"},{"key":"67","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1158\/1078-0432.CCR-10-2806","article-title":"Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors","volume":"17","author":"Rixe","year":"2011","journal-title":"Clin Cancer Res"},{"key":"68","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Yoshino","year":"2013","journal-title":"Lancet"},{"key":"69","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1200\/JCO.2012.45.0494","article-title":"Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial","volume":"31","author":"Spira","year":"2013","journal-title":"J Clin Oncol"},{"key":"70","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Schmidinger","year":"2016","journal-title":"Lancet Oncol"},{"key":"71","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1016\/j.humpath.2014.05.015","article-title":"Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature","volume":"45","author":"Seshan","year":"2014","journal-title":"Hum Pathol"},{"key":"72","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1093\/ndt\/gfr093","article-title":"Crescentic glomerulonephritis associated with vascular endothelial growth factor (VEGF) inhibitor and bisphosphonate administration","volume":"26","author":"Daphnis","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"73","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1093\/ndt\/gfp140","article-title":"Acute nephritic syndrome after anti-VEGF therapy for renal cell carcinoma","volume":"24","author":"Betjes","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"74","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1093\/ndt\/gfp666","article-title":"Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy","volume":"25","author":"Selgas","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"75","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000241551","article-title":"Nephrotic Syndrome and Acute Renal Failure Apparently Induced by Sunitinib","volume":"2","author":"Wang","year":"2009","journal-title":"Case Rep Oncol"},{"key":"76","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/ndt\/gfn625","article-title":"Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect?","volume":"24","author":"Marsh","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"77","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13104-016-1895-8","article-title":"The best objective response of target lesions and the incidence of treatment-related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: a Japanese retrospective study","volume":"9","author":"Nakai","year":"2016","journal-title":"BMC Res Notes"},{"key":"78","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/annonc\/mdn729","article-title":"Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma","volume":"20","author":"Joensuu","year":"2009","journal-title":"Ann Oncol"},{"key":"79","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1200\/jco.2008.26.15_suppl.3543","article-title":"Association of diastolic blood pressure (dBP) \u2265 90 mmHg with overall survival (OS) in patients treated with axitinib (AG- 013736)","volume":"26","author":"Spano","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"80","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1684\/bdc.2008.0705","article-title":"[Anti-angiogenic treatment in the management of metastatic renal cell carcinoma]. [Article in French]","volume":"95","author":"Ravaud","year":"2008","journal-title":"Bull Cancer"},{"key":"81","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s12885-015-1350-6","article-title":"Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancer","volume":"15","author":"Cebotaru","year":"2015","journal-title":"BMC Cancer"},{"key":"82","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-016-0332-8","article-title":"Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors","volume":"9","author":"Chi","year":"2016","journal-title":"J Hematol Oncol"},{"key":"83","doi-asserted-by":"publisher","first-page":"42076","DOI":"10.18632\/oncotarget.14942","article-title":"Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study","volume":"8","author":"Sai","year":"2017","journal-title":"Oncotarget"},{"key":"84","doi-asserted-by":"publisher","first-page":"975","DOI":"10.4161\/cbt.29187","article-title":"Dual VEGF\/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers","volume":"15","author":"Rini","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"85","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1038\/bjc.2014.541","article-title":"The combination of axitinib followed by paclitaxel\/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical\/correlative prospective phase II clinical trial","volume":"112","author":"Liu","year":"2015","journal-title":"Br J Cancer"},{"key":"86","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyw103","article-title":"Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patien ts from a randomized, double-blind phase II study","author":"Akaza","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"87","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11523-014-0307-z","article-title":"Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial","volume":"10","author":"Motzer","year":"2015","journal-title":"Target Oncol"},{"key":"88","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Topuzov","year":"2014","journal-title":"Lancet"},{"key":"89","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Taylor","year":"2015","journal-title":"N Engl J Med"},{"key":"90","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s00228-010-0815-4","article-title":"Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis","volume":"66","author":"Jiang","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"91","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/02841860802314720","article-title":"Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis","volume":"48","author":"Wu","year":"2009","journal-title":"Acta Oncol"},{"key":"92","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1470-2045(08)70003-2","article-title":"Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis","volume":"9","author":"Zhu","year":"2008","journal-title":"Lancet Oncol"},{"key":"93","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.2217\/fon.14.42","article-title":"Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis","volume":"10","author":"Fouad","year":"2014","journal-title":"Future Oncol"},{"key":"94","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.critrevonc.2014.06.003","article-title":"Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis","volume":"92","author":"Fouad","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"95","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00280-012-2025-5","article-title":"Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis","volume":"71","author":"Shen","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"96","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/jhh.2013.30","article-title":"Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis","volume":"27","author":"Galsky","year":"2013","journal-title":"J Hum Hypertens"},{"key":"97","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2174\/1573402112666160302101319","article-title":"Update of Targeted Therapy-Induced Hypertension: Basics for Non-Oncology Providers","volume":"12","author":"Marten","year":"2016","journal-title":"Curr Hypertens Rev"},{"key":"98","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13054-017-1678-1","article-title":"New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management","volume":"21","author":"Schellongowski","year":"2017","journal-title":"Crit Care"},{"key":"99","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/ijms17122073","article-title":"Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients","author":"Niemczyk","year":"2016","journal-title":"Int J Mol Sci"},{"key":"100","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/cncr.28972","article-title":"Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway","volume":"121","author":"Williams","year":"2015","journal-title":"Cancer"},{"key":"101","doi-asserted-by":"publisher","first-page":"6250","DOI":"10.1158\/1078-0432.CCR-09-0058","article-title":"Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment","volume":"15","author":"Ratain","year":"2009","journal-title":"Clin Cancer Res"},{"key":"102","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1056\/NEJMc072330","article-title":"Home blood-pressure monitoring in patients receiving sunitinib","volume":"358","author":"Oudard","year":"2008","journal-title":"N Engl J Med"},{"key":"103","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1038\/bjc.2014.430","article-title":"Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100","volume":"111","author":"Koller","year":"2014","journal-title":"Br J Cancer"},{"key":"104","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.dld.2014.12.013","article-title":"Vascular Endothelial Growth Factor A c.*237C>T polymorphism is associated with bevacizumab efficacy and related hypertension in metastatic colorectal cancer","volume":"47","author":"Dahan","year":"2015","journal-title":"Dig Liver Dis"},{"key":"105","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/jnci\/djq091","article-title":"Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"102","author":"Tang","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"106","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1200\/JCO.2009.25.4482","article-title":"Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599","volume":"28","author":"Johnson","year":"2010","journal-title":"J Clin Oncol"},{"key":"107","doi-asserted-by":"publisher","first-page":"4672","DOI":"10.1200\/JCO.2008.16.1612","article-title":"Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100","volume":"26","author":"Cobleigh","year":"2008","journal-title":"J Clin Oncol"},{"key":"108","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s12029-009-9104-9","article-title":"Evaluation of hypertension as a marker of bevacizumab efficacy","volume":"40","author":"He","year":"2009","journal-title":"J Gastrointest Cancer"},{"key":"109","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1093\/annonc\/mdn637","article-title":"Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab","volume":"20","author":"Cascinu","year":"2009","journal-title":"Ann Oncol"},{"key":"110","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1093\/annonc\/mdq221","article-title":"Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24","volume":"21","author":"Vincent","year":"2010","journal-title":"Ann Oncol"},{"key":"111","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/jnci\/djr128","article-title":"Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"103","author":"Motzer","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"112","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/COC.0b013e3182468039","article-title":"Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy","volume":"36","author":"Kim","year":"2013","journal-title":"Am J Clin Oncol"},{"key":"113","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1038\/bjc.2015.368","article-title":"Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients","volume":"113","author":"Rini","year":"2015","journal-title":"Br J Cancer"},{"key":"114","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s11060-009-0003-5","article-title":"Arterial hypertension and bevacizumab treatment in glioblastoma: no correlation with clinical outcome","volume":"97","author":"Wick","year":"2010","journal-title":"J Neurooncol"},{"key":"115","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1634\/theoncologist.2012-0339","article-title":"Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies","volume":"18","author":"Rosen","year":"2013","journal-title":"Oncologist"},{"key":"116","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00280-009-1170-y","article-title":"Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic\/pharmacodynamic meta-analysis","volume":"66","author":"Motzer","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"117","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s00280-011-1604-1","article-title":"Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients","volume":"68","author":"De Placido","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"118","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1093\/annonc\/mdm184","article-title":"Hypertension as a predictive factor of Sunitinib activity","volume":"18","author":"Izzedine","year":"2007","journal-title":"Ann Oncol"},{"key":"119","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1200\/JCO.2008.19.0108","article-title":"Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"120","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1200\/JCO.2007.10.8332","article-title":"Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity","volume":"26","author":"Chow","year":"2008","journal-title":"J Clin Oncol"},{"key":"121","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJMsa1616035","article-title":"Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control","volume":"377","author":"Ruiz-Negron","year":"2017","journal-title":"N Engl J Med"},{"key":"122","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"Taler","year":"2014","journal-title":"JAMA"},{"key":"123","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1161\/CIRCULATIONAHA.109.192064","article-title":"2009 focused update: ACCF\/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation","volume":"119","author":"Yancy","year":"2009","journal-title":"Circulation"},{"key":"124","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","article-title":"2013 ESH\/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"31","author":"Jaarsma","year":"2013","journal-title":"J Hypertens"},{"key":"125","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1001\/jama.291.20.2441","article-title":"Prognostic importance of comorbidity in a hospital-based cancer registry","volume":"291","author":"Spitznagel","year":"2004","journal-title":"JAMA"},{"key":"126","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"key":"127","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Levy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"128","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.cjca.2014.02.011","article-title":"Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome","volume":"30","author":"Touyz","year":"2014","journal-title":"Can J Cardiol"},{"key":"129","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.jacc.2015.07.025","article-title":"Vascular and Metabolic Implications of Novel Targeted Cancer Therapies: Focus on Kinase Inhibitors","volume":"66","author":"Moslehi","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"130","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/ajh.2010.25","article-title":"Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis","volume":"23","author":"Wu","year":"2010","journal-title":"Am J Hypertens"},{"key":"131","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1016\/S0140-6736(07)61840-6","article-title":"Cardiac toxicity of sunitinib","volume":"370","author":"Joensuu","year":"2007","journal-title":"Lancet"},{"key":"132","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1200\/JCO.2008.16.5274","article-title":"Doxorubicin cardiotoxicity in the elderly: old drugs and new opportunities","volume":"26","author":"Glick","year":"2008","journal-title":"J Clin Oncol"},{"key":"133","doi-asserted-by":"publisher","first-page":"CD006652","DOI":"10.1002\/14651858.CD006652.pub5","article-title":"Parenteral anticoagulation in ambulatory patients with cancer","volume":"9","author":"Schunemann","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"134","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217730129","article-title":"Assessment of venous thromboembolism treatment in patients with cancer on low molecular weight heparin, warfarin, and the direct oral anticoagulants","author":"Shapiro","year":"2017","journal-title":"J Oncol Pharm Pract"},{"key":"135","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217726158","article-title":"Single-center, retrospective evaluation of safety and efficacy of direct oral anticoagulants versus low-molecular-weight heparin and vitamin K antagonist in patients with cancer","author":"Hobaugh","year":"2017","journal-title":"J Oncol Pharm Pract"},{"key":"136","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217718382","article-title":"Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study","author":"Herrington","year":"2017","journal-title":"J Oncol Pharm Pract"},{"key":"137","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11239-017-1558-1","article-title":"Anticoagulation prescribing patterns in patients with cancer","volume":"45","author":"Papadopoulos","year":"2017","journal-title":"J Thromb Thrombolysis"},{"key":"138","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.amjmed.2017.06.026","article-title":"Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial","volume":"130","author":"Lopes","year":"2017","journal-title":"Am J Med"},{"key":"139","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/SPC.0000000000000309","article-title":"Advances in managing and preventing thromboembolic disease in cancer patients","volume":"11","author":"Bozas","year":"2017","journal-title":"Curr Opin Support Palliat Care"},{"key":"140","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1001\/jamainternmed.2017.5512","article-title":"Association of Warfarin Use With Lower Overall Cancer Incidence Among Patients Older Than 50 Years","volume":"177","author":"Lorens","year":"2017","journal-title":"JAMA Intern Med"},{"key":"141","doi-asserted-by":"publisher","first-page":"353","DOI":"10.20452\/pamw.3431","article-title":"Management of patients with atrial fibrillation and chronic kidney disease in light of the latest guidelines","volume":"126","author":"Malyszko","year":"2016","journal-title":"Pol Arch Med Wewn"},{"key":"142","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.mcna.2017.03.004","article-title":"Aspirin for Primary Prevention","volume":"101","author":"Owens","year":"2017","journal-title":"Med Clin North Am"},{"key":"143","unstructured":"Whitlock, Williams, Burda, Feightner, Beil. (2015). Aspirin Use in Adults: Cancer, All-Cause Mortality, and Harms: A Systematic Evidence Review for the US Preventive Services Task Force. (Rockville (MD)."},{"key":"144","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/AOG.0000000000001491","article-title":"Association of Low-Dose Aspirin and Survival of Women With Endometrial Cancer","volume":"128","author":"Roman","year":"2016","journal-title":"Obstet Gynecol"},{"key":"145","doi-asserted-by":"publisher","first-page":"10804","DOI":"10.1158\/0008-5472.CAN-07-2310","article-title":"Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells","volume":"67","author":"Sonenberg","year":"2007","journal-title":"Cancer Res"},{"key":"146","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ygyno.2008.04.008","article-title":"In vitro metformin anti-neoplastic activity in epithelial ovarian cancer","volume":"110","author":"Bruchim","year":"2008","journal-title":"Gynecol Oncol"},{"key":"147","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.cmet.2010.03.014","article-title":"Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner","volume":"11","author":"Thomas","year":"2010","journal-title":"Cell Metab"},{"key":"148","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1136\/bmj.38415.708634.F7","article-title":"Metformin and reduced risk of cancer in diabetic patients","volume":"330","author":"Morris","year":"2005","journal-title":"BMJ"},{"key":"149","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1158\/1940-6207.CAPR-10-0157","article-title":"Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis","volume":"3","author":"Gandini","year":"2010","journal-title":"Cancer Prev Res (Phila)"},{"key":"150","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.2337\/dc08-2175","article-title":"New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes","volume":"32","author":"Evans","year":"2009","journal-title":"Diabetes Care"},{"key":"151","doi-asserted-by":"publisher","first-page":"322","DOI":"10.2337\/dc09-1380","article-title":"Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16","volume":"33","author":"Bilo","year":"2010","journal-title":"Diabetes Care"},{"key":"152","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.2147\/TCRM.S91513","article-title":"Cancer risk in patients aged 30 years and above with type 2 diabetes receiving antidiabetic monotherapy: a cohort study using metformin as the comparator","volume":"11","author":"Tsai","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"153","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/IGC.0000000000000855","article-title":"The Effect of Metformin on Oncological Outcomes in Patients With Cervical Cancer With Type 2 Diabetes Mellitus","volume":"27","author":"Kornsilp","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"154","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1002\/hed.23743","article-title":"Effect of metformin on the incidence of head and neck cancer in diabetics","volume":"37","author":"Weng","year":"2015","journal-title":"Head Neck"},{"key":"155","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/CEJ.0000000000000246","article-title":"Metformin and the risk of renal cell carcinoma: a case-control analysis","volume":"26","author":"Bodmer","year":"2017","journal-title":"Eur J Cancer Prev"},{"key":"156","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/ijc.24054","article-title":"Hypertension is an independent predictor of survival disparity between African-American and white breast cancer patients","volume":"124","author":"Esserman","year":"2009","journal-title":"Int J Cancer"},{"key":"157","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1016\/j.jacc.2017.09.1095","article-title":"Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2","volume":"70","author":"Yeh","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"158","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ijcard.2017.02.154","article-title":"Practices in management of cancer treatment-related cardiovascular toxicity: A cardio-oncology survey","volume":"241","author":"Barlesi","year":"2017","journal-title":"Int J Cardiol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.25024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T12:35:09Z","timestamp":1589027709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.25024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,17]]},"references-count":158,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2018,4,17]]}},"alternative-id":["25024","29755695"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.25024","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,17]]}}}